# Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-of-omalizumab-for-the-treatment-of-chronic-spontaneous/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Tim A. Kanters,H. Bing Thio,L. Hakkaart |
| Citations | 33 |
| DOI | 10.1111/bjd.16476 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjd.16476 |
| OpenAlex ID | https://openalex.org/W2794108735 |
| PMID | 29476533 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Tim A. Kanters](https://scholariq.org/researchers/tim-a-kanters/)

## Paper journal

- [British Journal of Dermatology](https://scholariq.org/journals/british-journal-of-dermatology/)

## Paper primary topic

- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)

## Paper topics

- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)
- [Coagulation, Bradykinin, Polyphosphates, and Angioedema](https://scholariq.org/topics/coagulation-bradykinin-polyphosphates-and-angioedema/)
- [Mast cells and histamine](https://scholariq.org/topics/mast-cells-and-histamine/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.